Penthrox Dosing for Acute Pain Relief
For adults and children aged 5-16 years with acute trauma-related pain, administer methoxyflurane (Penthrox) as a single 3 mL dose via the Penthrox inhaler, with a maximum of 6 mL per day (two 3 mL inhalers) and 15 mL per week. 1
Administration Details
Standard Dosing Protocol
- Initial dose: 3 mL via Penthrox inhaler, self-administered by inhalation
- Second dose: An additional 3 mL inhaler may be provided upon request if pain relief is inadequate
- Daily maximum: 6 mL (two inhalers)
- Weekly maximum: 15 mL 1, 2
Age-Specific Considerations
Children aged 6-17 years: The same dosing applies as for adults (3 mL per inhaler, maximum 6 mL/day). The MAGPIE trial demonstrated efficacy and safety in this pediatric population with a mean age of 11.1 years 1.
Children aged 5 years: While the expanded question mentions children aged 5-16 years, the strongest evidence is for ages 6-17 years. For 5-year-olds, clinical judgment should guide use, as they fall just outside the primary trial age range.
Clinical Efficacy Timeline
Pain relief onset is rapid:
- Median time to first pain relief: 3 minutes 3
- Peak effect: 15 minutes after initiation, with a treatment difference of -18.5 mm on VAS compared to placebo 2
- Sustained effect: Significant pain reduction maintained through 20 minutes 3, 2
Safety Profile
The safety margin is substantial. The maximum analgesic dose (6 mL/day) produces 0.59 MAC-hours, well below the 2.0 MAC-hours threshold associated with renal toxicity—providing at least a 2.7 to 8-fold safety margin 4.
Common Side Effects (Generally Mild and Self-Limiting)
Critical safety note: No serious adverse events related to methoxyflurane were reported in the pediatric trial 1. In a large retrospective cohort of 9,472 children treated with methoxyflurane, adverse drug reactions were rare (<0.1%), with no cases of liver or kidney toxicity observed 6.
Administration Technique
The device is self-administered by the patient:
- Patient inhales through the Penthrox inhaler as needed for pain
- The inhaler contains an activated carbon chamber that vaporizes the liquid methoxyflurane
- Continuous or intermittent inhalation is possible based on pain intensity
- Treatment typically continues until pain is adequately controlled or the inhaler is empty
When to Avoid or Use Caution
While not explicitly contraindicated in the provided evidence, standard precautions for volatile anesthetics apply. The device should be used in well-ventilated areas, and patients should be monitored for the expected pharmacological effects (dizziness, mild euphoria).
Rescue Medication
In the MAGPIE trial, only 9.8% of methoxyflurane-treated patients required rescue medication compared to 30.0% in the placebo group 1, indicating high efficacy as a standalone analgesic for acute trauma pain.